Park Place Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Park Place Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82K	Hold	1,433	–	–	0.01%	347
2026 Q1	$81K	Buy	+1,433	New	+$83.6K	0.02%	291
2024 Q3	–	Sell	-18	Closed	-$1.48K	–	861
2024 Q2	$1.48K	Hold	18	–	–	﹤0.01%	810
2024 Q1	$1.57K	Hold	18	–	–	﹤0.01%	852
2023 Q4	$1.74K	Hold	18	–	–	﹤0.01%	809
2023 Q3	$1.59K	Hold	18	–	–	﹤0.01%	948
2023 Q2	$1.56K	Hold	18	–	–	﹤0.01%	968
2023 Q1	$1.75K	Hold	18	–	–	﹤0.01%	957
2022 Q4	$2K	Buy	+18	New	+$1.69K	﹤0.01%	939

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Park Place Capital's BMRN Position: Q2 2026 in Review

Park Place Capital held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1,433 shares worth $82K. The position accounts for 0.01% of the portfolio, ranked #347.

Park Place Capital first reported a position in BMRN in Q4 2022 and has held it in 9 quarters since. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Park Place Capital held 1,433 shares of BioMarin Pharmaceuticals worth $82K as of Q2 2026.
Park Place Capital left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.01% of Park Place Capital's portfolio in Q2 2026, its #347 holding.
Park Place Capital first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.